![]()
Our mission is to develop affordable cell- and gene-based therapies with improved safety and better efficacy to help patients fight cancers and achieve long-term remission.
Our vision is to lead the industry of cell and gene therapies in China and worldwide and advance the current cancer treatment guidelines by pushing the CAR-T cell therapy from last line to front line of cancer treatment by reasons of affordability, better safety and efficacy, least side effect, and long-term remission.
As a cutting-edge medical research institute in immunotherapy and gene therapy in China, GIMI has registered more than 40 clinical trials in ClinicalTrials.gov. The multi-center trial hospitals include Aero Space Center Hospital (ASCH, Beijing), Beijing Jingdu Children’s Hospital, 301 Hospital, Beijing Puhua International Hospital, Zhujiang Hospital of Southern Medical University (Guangzhou), Peking University Shenzhen Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital of Southern Medical University, The Second Affiliated Hospital of Hainan Medical University, etc.
GIMI has established close alliance with Nagoya University Hospital in Japan, Siriraj Hospital of Mahidol University in Thailand and National Research Center for Hematology in Russia to prove the affordability and feasibility of CAR-T cell therapy technologies in an international platform.
GIMI has presented its promising clinical trial results in the American Society of Hematology (ASH) Annual Meetings since 2014.
For further inquiry, please contact GIMI at c@szgimi.org.
